Development of an optimized conditionally replicative adenoviral agent for ovarian cancer

Zeng B. Zhu, Baogen Lu, Miey Park, Sharmila K. Makhija, Thomas M. Numnum, James E. Kendrick, Minghui Wang, Yuko Tsuruta, Paul Fisher, Ronald D. Alvarez, Fen Zhou, Gene P. Siegal, Hongju Wu, David T. Curiel

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Human ovarian cancer is a highly lethal malignant neoplasm in woman with no effective treatment if conventional chemotherapy fails. In this regard, conditionally replicative adenoviruses (CRAds) represent a promising new modality for the treatment of cancer. A key contribution to the development of CRAds was the introduction of tumor-selective viral replication to restrict amplification to the neoplastic cell population. Under ideal conditions following cellular infection, the viruses replicate selectively in the infected tumor cells, killing the cells by cytolysis, leaving normal cells unaffected. However, to date, there have been limitations to the clinical application of these CRAd agents i.e. poor viral infectivity, poor tumor specificity and high toxicity. Here, we report the in vitro and in vivo comparison of four CRAd agents developed for ovarian cancer application, specifically, Ad-Δ24.F5/3, CRAd-C.F5/3, CRAd-M.F5/3 and CRAd-S.F5/3. All CRAd agents contained fiber knob chimeras of adenovirus serotype 3, which enhanced the viral infectivity at the transductional level via a non-Coxsackie-Adenovirus Receptor alternative pathway. In addition, these CRAds embodied distinct mechanisms for the achievement of replication specificity. Tumor cell killing was assessed by using an oncolytic assay and a cell viability assay (MTS) in vitro, while tumor growth was examined in a xenograft model in vivo by using a bioluminescent imaging assay. In addition, the replication rates of the CRAd agents were determined in human liver slices. Both the Ad-Δ24.F5/3 and CRAd-S.F5/3 were demonstrated to have higher tumor killing effects in tumor cells and a lower viral replication rate in human liver. These agents are thus excellent candidates for clinical trials of CRAd agents against human ovarian cancer.

Original languageEnglish (US)
Pages (from-to)1179-1188
Number of pages10
JournalInternational Journal of Oncology
Volume32
Issue number6
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Adenoviridae
Ovarian Neoplasms
Neoplasms
Luminescent Measurements
Liver
Virus Diseases
Heterografts
Cell Survival
Clinical Trials
Drug Therapy

Keywords

  • Adenovirus
  • Conditionally replicative adenovirus
  • Fiber modification
  • Tumor specific promoter

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. / Zhu, Zeng B.; Lu, Baogen; Park, Miey; Makhija, Sharmila K.; Numnum, Thomas M.; Kendrick, James E.; Wang, Minghui; Tsuruta, Yuko; Fisher, Paul; Alvarez, Ronald D.; Zhou, Fen; Siegal, Gene P.; Wu, Hongju; Curiel, David T.

In: International Journal of Oncology, Vol. 32, No. 6, 06.2008, p. 1179-1188.

Research output: Contribution to journalArticle

Zhu, ZB, Lu, B, Park, M, Makhija, SK, Numnum, TM, Kendrick, JE, Wang, M, Tsuruta, Y, Fisher, P, Alvarez, RD, Zhou, F, Siegal, GP, Wu, H & Curiel, DT 2008, 'Development of an optimized conditionally replicative adenoviral agent for ovarian cancer', International Journal of Oncology, vol. 32, no. 6, pp. 1179-1188. https://doi.org/10.3892/ijo_32_6_1179
Zhu, Zeng B. ; Lu, Baogen ; Park, Miey ; Makhija, Sharmila K. ; Numnum, Thomas M. ; Kendrick, James E. ; Wang, Minghui ; Tsuruta, Yuko ; Fisher, Paul ; Alvarez, Ronald D. ; Zhou, Fen ; Siegal, Gene P. ; Wu, Hongju ; Curiel, David T. / Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. In: International Journal of Oncology. 2008 ; Vol. 32, No. 6. pp. 1179-1188.
@article{c814cabf8c094e619e661e3097572865,
title = "Development of an optimized conditionally replicative adenoviral agent for ovarian cancer",
abstract = "Human ovarian cancer is a highly lethal malignant neoplasm in woman with no effective treatment if conventional chemotherapy fails. In this regard, conditionally replicative adenoviruses (CRAds) represent a promising new modality for the treatment of cancer. A key contribution to the development of CRAds was the introduction of tumor-selective viral replication to restrict amplification to the neoplastic cell population. Under ideal conditions following cellular infection, the viruses replicate selectively in the infected tumor cells, killing the cells by cytolysis, leaving normal cells unaffected. However, to date, there have been limitations to the clinical application of these CRAd agents i.e. poor viral infectivity, poor tumor specificity and high toxicity. Here, we report the in vitro and in vivo comparison of four CRAd agents developed for ovarian cancer application, specifically, Ad-Δ24.F5/3, CRAd-C.F5/3, CRAd-M.F5/3 and CRAd-S.F5/3. All CRAd agents contained fiber knob chimeras of adenovirus serotype 3, which enhanced the viral infectivity at the transductional level via a non-Coxsackie-Adenovirus Receptor alternative pathway. In addition, these CRAds embodied distinct mechanisms for the achievement of replication specificity. Tumor cell killing was assessed by using an oncolytic assay and a cell viability assay (MTS) in vitro, while tumor growth was examined in a xenograft model in vivo by using a bioluminescent imaging assay. In addition, the replication rates of the CRAd agents were determined in human liver slices. Both the Ad-Δ24.F5/3 and CRAd-S.F5/3 were demonstrated to have higher tumor killing effects in tumor cells and a lower viral replication rate in human liver. These agents are thus excellent candidates for clinical trials of CRAd agents against human ovarian cancer.",
keywords = "Adenovirus, Conditionally replicative adenovirus, Fiber modification, Tumor specific promoter",
author = "Zhu, {Zeng B.} and Baogen Lu and Miey Park and Makhija, {Sharmila K.} and Numnum, {Thomas M.} and Kendrick, {James E.} and Minghui Wang and Yuko Tsuruta and Paul Fisher and Alvarez, {Ronald D.} and Fen Zhou and Siegal, {Gene P.} and Hongju Wu and Curiel, {David T.}",
year = "2008",
month = "6",
doi = "10.3892/ijo_32_6_1179",
language = "English (US)",
volume = "32",
pages = "1179--1188",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Development of an optimized conditionally replicative adenoviral agent for ovarian cancer

AU - Zhu, Zeng B.

AU - Lu, Baogen

AU - Park, Miey

AU - Makhija, Sharmila K.

AU - Numnum, Thomas M.

AU - Kendrick, James E.

AU - Wang, Minghui

AU - Tsuruta, Yuko

AU - Fisher, Paul

AU - Alvarez, Ronald D.

AU - Zhou, Fen

AU - Siegal, Gene P.

AU - Wu, Hongju

AU - Curiel, David T.

PY - 2008/6

Y1 - 2008/6

N2 - Human ovarian cancer is a highly lethal malignant neoplasm in woman with no effective treatment if conventional chemotherapy fails. In this regard, conditionally replicative adenoviruses (CRAds) represent a promising new modality for the treatment of cancer. A key contribution to the development of CRAds was the introduction of tumor-selective viral replication to restrict amplification to the neoplastic cell population. Under ideal conditions following cellular infection, the viruses replicate selectively in the infected tumor cells, killing the cells by cytolysis, leaving normal cells unaffected. However, to date, there have been limitations to the clinical application of these CRAd agents i.e. poor viral infectivity, poor tumor specificity and high toxicity. Here, we report the in vitro and in vivo comparison of four CRAd agents developed for ovarian cancer application, specifically, Ad-Δ24.F5/3, CRAd-C.F5/3, CRAd-M.F5/3 and CRAd-S.F5/3. All CRAd agents contained fiber knob chimeras of adenovirus serotype 3, which enhanced the viral infectivity at the transductional level via a non-Coxsackie-Adenovirus Receptor alternative pathway. In addition, these CRAds embodied distinct mechanisms for the achievement of replication specificity. Tumor cell killing was assessed by using an oncolytic assay and a cell viability assay (MTS) in vitro, while tumor growth was examined in a xenograft model in vivo by using a bioluminescent imaging assay. In addition, the replication rates of the CRAd agents were determined in human liver slices. Both the Ad-Δ24.F5/3 and CRAd-S.F5/3 were demonstrated to have higher tumor killing effects in tumor cells and a lower viral replication rate in human liver. These agents are thus excellent candidates for clinical trials of CRAd agents against human ovarian cancer.

AB - Human ovarian cancer is a highly lethal malignant neoplasm in woman with no effective treatment if conventional chemotherapy fails. In this regard, conditionally replicative adenoviruses (CRAds) represent a promising new modality for the treatment of cancer. A key contribution to the development of CRAds was the introduction of tumor-selective viral replication to restrict amplification to the neoplastic cell population. Under ideal conditions following cellular infection, the viruses replicate selectively in the infected tumor cells, killing the cells by cytolysis, leaving normal cells unaffected. However, to date, there have been limitations to the clinical application of these CRAd agents i.e. poor viral infectivity, poor tumor specificity and high toxicity. Here, we report the in vitro and in vivo comparison of four CRAd agents developed for ovarian cancer application, specifically, Ad-Δ24.F5/3, CRAd-C.F5/3, CRAd-M.F5/3 and CRAd-S.F5/3. All CRAd agents contained fiber knob chimeras of adenovirus serotype 3, which enhanced the viral infectivity at the transductional level via a non-Coxsackie-Adenovirus Receptor alternative pathway. In addition, these CRAds embodied distinct mechanisms for the achievement of replication specificity. Tumor cell killing was assessed by using an oncolytic assay and a cell viability assay (MTS) in vitro, while tumor growth was examined in a xenograft model in vivo by using a bioluminescent imaging assay. In addition, the replication rates of the CRAd agents were determined in human liver slices. Both the Ad-Δ24.F5/3 and CRAd-S.F5/3 were demonstrated to have higher tumor killing effects in tumor cells and a lower viral replication rate in human liver. These agents are thus excellent candidates for clinical trials of CRAd agents against human ovarian cancer.

KW - Adenovirus

KW - Conditionally replicative adenovirus

KW - Fiber modification

KW - Tumor specific promoter

UR - http://www.scopus.com/inward/record.url?scp=48149099957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48149099957&partnerID=8YFLogxK

U2 - 10.3892/ijo_32_6_1179

DO - 10.3892/ijo_32_6_1179

M3 - Article

VL - 32

SP - 1179

EP - 1188

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -